

# Sibylle Loibl

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/712130/sibylle-loibl-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

257  
papers

29,763  
citations

72  
h-index

171  
g-index

275  
ext. papers

38,375  
ext. citations

9.1  
avg. IF

6.65  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 257 | Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, 325-328   | 21.7 | 0         |
| 256 | Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 185-201  | 7.5  | 2         |
| 255 | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 219-228                           | 7.5  | 0         |
| 254 | Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. <i>European Journal of Cancer</i> , <b>2022</b> , 170, 54-63   | 7.5  |           |
| 253 | Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 1-13  | 7.1  | 0         |
| 252 | Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , <b>2021</b> , | 7.5  | 1         |
| 251 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 150  | 7.8  | 17        |
| 250 | AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2021</b> , 81, 1112-1120  | 2    | 2         |
| 249 | AGO Algorithms for the Treatment of Breast Cancer: Update 2021. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2021</b> , 81, 1101-1111  | 2    | 2         |
| 248 | Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrightNess Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 603-608  | 13.4 | 19        |
| 247 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1529-1541   | 59.2 | 108       |
| 246 | Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 565-572  | 13.4 | 8         |
| 245 | Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 2778-2796   | 12.7 | 13        |
| 244 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1485-1505   | 2.2  | 102       |
| 243 | Breast cancer. <i>Lancet, The</i> , <b>2021</b> , 397, 1750-1769   | 40   | 126       |
| 242 | Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS602-TPS602   | 2.2  | 1         |
| 241 | Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St.Gallen Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2021</b> , 81, 637-653   | 2    | 1         |

|     |  |      |     |
|-----|--|------|-----|
| 240 | Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 519-519             | 2.2  | 2   |
| 239 | Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1518-1530  | 2.2  | 35  |
| 238 | Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 159-170  | 7.5  | 12  |
| 237 | Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie. <i>Onkologe</i> , <b>2021</b> , 27, 820  | 0.1  |     |
| 236 | Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2394-2405   | 59.2 | 145 |
| 235 | The definition of pregnancy-associated breast cancer is outdated and should no longer be used. <i>Lancet Oncology</i> , <b>2021</b> , 22, 753-754  | 21.7 | 13  |
| 234 | Patient-Reported Outcomes in Patients With -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2005-2015        | 2.2  | 7   |
| 233 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2796-2811                    | 24.4 | 10  |
| 232 | Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 193-203                | 7.5  | 2   |
| 231 | A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 15-23             | 4.4  | 2   |
| 230 | Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 504-512                                   | 12.9 | 3   |
| 229 | Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , <b>2021</b> , 22, e18-e28   | 21.7 | 13  |
| 228 | Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2584-2591 | 12.9 | 10  |
| 227 | Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2148-2158                           | 12.9 | 3   |
| 226 | Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 212-222                                      | 21.7 | 64  |
| 225 | Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1151-1161                 | 21.7 | 32  |
| 224 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1139-1150   | 21.7 | 24  |
| 223 | Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 13-24  | 7.5  | 2   |

|     |   |      |     |
|-----|---|------|-----|
| 222 | A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 3911-3924  | 3.6  | 2   |
| 221 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1291-1301   | 13.4 | 5   |
| 220 | Reply to Y. Kawamura et al. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3090-3091   | 2.2  | 0   |
| 219 | Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective-Reply. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1403-1404  | 13.4 | 1   |
| 218 | HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply. <i>Lancet Oncology</i> , <b>2021</b> , 22, e427   | 21.7 | 3   |
| 217 | Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , <b>2021</b> , 32, 1216-1235                               | 10.3 | 44  |
| 216 | Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). <i>European Journal of Cancer</i> , <b>2021</b> , 156, 138-148  | 7.5  | 1   |
| 215 | Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. <i>Data in Brief</i> , <b>2021</b> , 38, 107354  | 1.2  | 0   |
| 214 | AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , <b>2021</b> , 16, 228-235   | 2.4  | 7   |
| 213 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , <b>2021</b> , 16, 214-227   | 2.4  | 19  |
| 212 | Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2020</b> , 80, 1229-1236             | 2    | 2   |
| 211 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2610-2619          | 2.2  | 134 |
| 210 | Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 694-697   | 8.7  | 29  |
| 209 | Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 744-748   | 12.4 | 21  |
| 208 | A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1896-1904   | 12.9 | 7   |
| 207 | Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. <i>Breast Care</i> , <b>2020</b> , 15, 217-226  | 2.4  | 8   |
| 206 | AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , <b>2020</b> , 15, 294-309   | 2.4  | 30  |
| 205 | PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. <i>Cancer Research and Treatment</i> , <b>2020</b> , 52, 689-696 | 5.2  | 17  |

|     |  |      |     |
|-----|--|------|-----|
| 204 | Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. <i>JAMA Surgery</i> , <b>2020</b> , 155, e195410   | 5.4  | 31  |
| 203 | Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 266-276   | 7.5  | 6   |
| 202 | Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Breast Care</i> 2019; Doi 10.1159/000500620. <i>Breast Care</i> , <b>2020</b> , 15, 96-101   | 2.4  | 1   |
| 201 | Corrigendum to Efficacy and safety of palbociclib (P) in patients (pts) ≥ 50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies [Breast 41S1 (2018) 511182]. <i>Breast</i> , <b>2020</b> , 49, 131 | 3.6  | 78  |
| 200 | CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 191-192   | 21.7 | 5   |
| 199 | Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , <b>2020</b> , 126, 1175-1182  | 6.4  | 7   |
| 198 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet, The</i> , <b>2020</b> , 395, 117-122   | 4.0  | 54  |
| 197 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 597-609   | 59.2 | 396 |
| 196 | Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e018143   | 6    | 5   |
| 195 | MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238021   | 3.7  | 3   |
| 194 | Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncologica</i> , <b>2020</b> , 59, 75-81   | 3.2  | 6   |
| 193 | Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 223-228   | 3.6  | 3   |
| 192 | Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , <b>2020</b> , 126, 3132-3139                            | 6.4  | 7   |
| 191 | Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 354-363  | 12.9 | 19  |
| 190 | The rise of oncology biosimilars: from process to promise. <i>Future Oncology</i> , <b>2019</b> , 15, 3255-3265  | 3.6  | 3   |
| 189 | AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. <i>Breast Care</i> , <b>2019</b> , 14, 247-255  | 2.4  | 23  |
| 188 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , <b>2019</b> , 14, 224-245  | 2.4  | 53  |
| 187 | Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , <b>2019</b> , 65, 1405-1413  | 5.5  | 31  |

|     |   |      |     |
|-----|---|------|-----|
| 186 | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparqinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 857-868                             | 7.5  | 9   |
| 185 | Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2019</b> , 79, 605-617   | 2    | 17  |
| 184 | Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 557-568 | 4.4  | 5   |
| 183 | Breast cancer, placenta and pregnancy. <i>European Journal of Cancer</i> , <b>2019</b> , 115, 68-78   | 7.5  | 16  |
| 182 | Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1929-1940   | 59.2 | 853 |
| 181 | NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2226-2234  | 2.2  | 61  |
| 180 | Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2257-2269  | 2.2  | 69  |
| 179 | Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1490-1498                                  | 2.2  | 12  |
| 178 | Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPR. <i>Breast Care</i> , <b>2019</b> , 14, 165-169  | 2.4  | 2   |
| 177 | Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3986-3995  | 12.9 | 21  |
| 176 | Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1169-1178   | 2.2  | 127 |
| 175 | Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 647-657  | 8.7  | 28  |
| 174 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , <b>2019</b> , 393, 1440-1452                         | 40   | 137 |
| 173 | Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 3892-3901  | 3.1  | 17  |
| 172 | Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2019</b> , 79, 1110-1117   | 2    | 0   |
| 171 | Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1012-1012   | 2.2  | 21  |
| 170 | Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 510-510  | 2.2  | 4   |
| 169 | A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, 394-401                     | 2.4  | 3   |

|     |  |      |     |
|-----|--|------|-----|
| 168 | Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 1009-1015   | 8.7  | 6   |
| 167 | Post-Neoadjuvant Therapy. <i>Breast Care</i> , <b>2019</b> , 14, 409-413   | 2.4  |     |
| 166 | Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 142  | 8.3  | 12  |
| 165 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , <b>2019</b> , 104, 21-34   | 11   | 363 |
| 164 | Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 301-305   | 8.7  | 17  |
| 163 | Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , <b>2019</b> , 38, 835-844   | 4    | 17  |
| 162 | Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , <b>2019</b> , 106, 181-192                    | 7.5  | 49  |
| 161 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 617-628   | 59.2 | 832 |
| 160 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , <b>2019</b> , 48, 795-806  | 7.8  | 52  |
| 159 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 497-509   | 21.7 | 341 |
| 158 | Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3358-3365  | 12.9 | 9   |
| 157 | Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. <i>Modern Pathology</i> , <b>2018</b> , 31, 607-615  | 9.8  | 14  |
| 156 | Neoadjuvant chemotherapy for early breast cancer. <i>Lancet Oncology</i> , <b>2018</b> , 19, e129  | 21.7 | 5   |
| 155 | Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 167, 59-71   | 4.4  | 23  |
| 154 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 968-978  | 36.3 | 101 |
| 153 | Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 568-568 | 2.2  | 2   |
| 152 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , <b>2018</b> , 19, 27-39  | 21.7 | 413 |
| 151 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology</i> , <b>2018</b> , 19, 40-50  | 21.7 | 730 |

|     |   |      |     |
|-----|---|------|-----|
| 150 | Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 343-358   | 4.9  | 6   |
| 149 | Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 127-138   | 21.7 | 62  |
| 148 | Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Oncotarget</i> , <b>2018</b> , 9, 15168-15175   | 3.3  | 15  |
| 147 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2281-2287  | 2.2  | 56  |
| 146 | Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1981-1990                                      | 2.2  | 172 |
| 145 | Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1308-1316   | 2.2  | 30  |
| 144 | Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. <i>Breast Care</i> , <b>2018</b> , 13, 440-446   | 2.4  | 1   |
| 143 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2018</b> , 78, 1056-1088 | 2    | 44  |
| 142 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1926-1936  | 59.2 | 478 |
| 141 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1390-1403  | 24.4 | 231 |
| 140 | The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , <b>2018</b> , 42, 41-49   | 3.6  | 49  |
| 139 | Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 67, 71-77   | 14.4 | 38  |
| 138 | Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. <i>Oncologist</i> , <b>2018</b> , 23, 974-981  | 5.7  | 13  |
| 137 | pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. <i>Breast</i> , <b>2017</b> , 32, 73-78   | 3.6  | 5   |
| 136 | Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 143-151   | 5.1  | 2   |
| 135 | Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. <i>Breast</i> , <b>2017</b> , 31, 202-207  | 3.6  | 38  |
| 134 | Efficacy and safety of nab-paclitaxel 125µmg/m and nab-paclitaxel 150µmg/m compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 163, 495-506   | 4.4  | 17  |
| 133 | HER2-positive breast cancer. <i>Lancet, The</i> , <b>2017</b> , 389, 2415-2429  | 40   | 351 |



|     |   |      |     |
|-----|---|------|-----|
| 132 | Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , <b>2017</b> , 389, 2403-2414  | 40   | 112 |
| 131 | Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , <b>2017</b> , 551, 92-94  | 50.4 | 643 |
| 130 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 1767-1778   | 36.3 | 186 |
| 129 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1378-1385   | 13.4 | 210 |
| 128 | Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). <i>European Journal of Cancer</i> , <b>2017</b> , 84, 1-8   | 7.5  | 10  |
| 127 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma  | 5.1  | 299 |
| 126 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research</i> , <b>2017</b> , 23, 5384-5393 | 5.1  | 293 |
| 125 | Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , <b>2017</b> , 22, 1028-1038  | 12.9 | 58  |
| 124 | Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1888-1896   | 5.7  | 83  |
| 123 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2961-8  | 27.4 | 58  |
| 122 | Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, 444-455   | 2.2  | 420 |
| 121 | Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 65-74   | 3    | 5   |
| 120 | Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2675-83   | 7.5  | 27  |
| 119 | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 345-356  | 12.9 | 35  |
| 118 | Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 43, 19-26  | 21.7 | 234 |
| 117 | Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , <b>2016</b> , 26, 87-99  | 14.4 | 38  |
| 116 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , <b>2016</b> , 7, 67686-67698  | 3.6  | 84  |
| 115 |   | 3.3  | 36  |

|     |  |      |     |
|-----|--|------|-----|
| 114 | loncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. <i>Oncotarget</i> , <b>2016</b> , 7, 13236-47   | 3.3  | 17  |
| 113 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , <b>2016</b> , 29, 1155-64  | 9.8  | 154 |
| 112 | Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5747-5754  | 12.9 | 116 |
| 111 | Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. <i>Breast Care</i> , <b>2016</b> , 11, 96-100  | 2.4  | 25  |
| 110 | Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5238-5248   | 12.9 | 30  |
| 109 | Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 149, 141-9  | 4.4  | 18  |
| 108 | Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 1118-27                         | 3.1  | 55  |
| 107 | Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 150, 127-39   | 4.4  | 69  |
| 106 | Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 152, 377-87                  | 4.4  | 52  |
| 105 | Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. <i>JAMA Oncology</i> , <b>2015</b> , 1, 1145-53  | 13.4 | 117 |
| 104 | Evolution of adjuvant chemotherapy for breast cancer. <i>Lancet, The</i> , <b>2015</b> , 385, 1812-4   | 4.0  | 3   |
| 103 | 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. <i>Breast Care</i> , <b>2015</b> , 10, 211-9   | 2.4  | 31  |
| 102 | Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2924-31 | 12.9 | 31  |
| 101 | Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2015</b> , 27, 85-91  | 2.4  | 11  |
| 100 | A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). <i>Cancer</i> , <b>2015</b> , 121, 3639-48             | 6.4  | 39  |
| 99  | Classical pathology and mutational load of breast cancer - integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , <b>2015</b> , 1, 225-38   | 5.3  | 57  |
| 98  | Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1565-70  | 8.7  | 60  |
| 97  | Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3651-7  | 12.9 | 73  |

|    |  |      |      |
|----|--|------|------|
| 96 | Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2981-8                                      | 7.5  | 26   |
| 95 | Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 209-19  | 59.2 | 940  |
| 94 | Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 983-91  | 2.2  | 650  |
| 93 | Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. <i>Current Breast Cancer Reports</i> , <b>2015</b> , 7, 203-209   | 0.8  | 2    |
| 92 | Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , <b>2015</b> , 6, 30306-16  | 3.3  | 11   |
| 91 | The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?. <i>JAMA Oncology</i> , <b>2015</b> , 1, 455-6   | 13.4 | 1    |
| 90 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , <b>2014</b> , 384, 164-72  | 40   | 2177 |
| 89 | Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 144, 153-62  | 4.4  | 73   |
| 88 | First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , <b>2014</b> , 23, 209-20   | 30   | 108  |
| 87 | PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3212-20       | 2.2  | 189  |
| 86 | Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 147, 61-8 | 4.4  | 90   |
| 85 | RANK expression as a prognostic and predictive marker in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 145, 307-15  | 4.4  | 41   |
| 84 | Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 2517-24   | 3.1  | 21   |
| 83 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 747-56  | 21.7 | 603  |
| 82 | The importance of supportive care in breast cancer patients. <i>Breast Care</i> , <b>2014</b> , 9, 230-1   | 2.4  | 13   |
| 81 | Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. <i>Breast Care</i> , <b>2014</b> , 9, 169-74   | 2.4  | 8    |
| 80 | Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. <i>Oncolmmunology</i> , <b>2014</b> , 3, e27926   | 7.2  | 17   |
| 79 | Predictive factors for response to neoadjuvant therapy in breast cancer. <i>Oncology Research and Treatment</i> , <b>2014</b> , 37, 563-8  | 2.8  | 17   |

|    |   |      |      |
|----|---|------|------|
| 78 | Adverse event management of oral mucositis in patients with breast cancer. <i>Breast Care</i> , <b>2014</b> , 9, 232-7  | 2.4  | 6    |
| 77 | Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 1725-33   | 7.5  | 29   |
| 76 | Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. <i>Oncotarget</i> , <b>2014</b> , 5, 9952-65   | 3.3  | 52   |
| 75 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 139, 779-87 | 4.4  | 19   |
| 74 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2206-23   | 10.3 | 2048 |
| 73 | Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 2047-56   | 4.9  | 26   |
| 72 | Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. <i>Archives of Gynecology and Obstetrics</i> , <b>2013</b> , 288, 1203-12  | 2.5  | 8    |
| 71 | Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2284-93           | 7.5  | 71   |
| 70 | 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). <i>Breast Care</i> , <b>2013</b> , 8, 221-9   | 2.4  | 65   |
| 69 | Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 1681-9  | 4.9  | 13   |
| 68 | Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer. <i>Breast Care</i> , <b>2013</b> , 8, 60-6  | 2.4  | 21   |
| 67 | Response-guided neoadjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3623-30   | 2.2  | 231  |
| 66 | Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2013</b> , 25, 66-73  | 2.4  | 17   |
| 65 | Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2532-9   | 2.2  | 198  |
| 64 | Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4521-31   | 12.9 | 110  |
| 63 | Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e79775  | 3.7  | 149  |
| 62 | Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 81, 136-50  | 7    | 13   |
| 61 | Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 27-34  | 6.3  | 4    |

|    |   |      |      |
|----|---|------|------|
| 60 | Breast cancer in pregnancy. <i>Lancet, The</i> , <b>2012</b> , 379, 570-9   | 40   | 160  |
| 59 | Treatment of breast cancer during pregnancy: an observational study. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 887-96   | 21.7 | 177  |
| 58 | Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e148-60                              | 21.7 | 418  |
| 57 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 135-44  | 21.7 | 363  |
| 56 | Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 299-309   | 59.2 | 411  |
| 55 | Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1796-804   | 2.2  | 1560 |
| 54 | Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. <i>Journal of Proteome Research</i> , <b>2012</b> , 11, 850-60                                 | 5.6  | 58   |
| 53 | Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40). <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 132, 863-70     | 4.4  | 33   |
| 52 | Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 387-91  | 4.4  | 50   |
| 51 | Being Pregnant and Diagnosed with Breast Cancer. <i>Breast Care</i> , <b>2012</b> , 7, 204-209  | 2.4  | 9    |
| 50 | Present status of adjuvant chemotherapy for elderly breast cancer patients. <i>Breast Care</i> , <b>2012</b> , 7, 439-442   | 2.4  | 3    |
| 49 | Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. <i>Breast Care</i> , <b>2011</b> , 6, 265-272  | 2.4  | 11   |
| 48 | Opinions on the ASCO 2011 Annual Meeting. <i>Breast Care</i> , <b>2011</b> , 6, 315-319   | 2.4  | 1    |
| 47 | Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. <i>Breast Care</i> , <b>2011</b> , 6, 279-283   | 2.4  | 11   |
| 46 | Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 145-56  | 4.4  | 193  |
| 45 | Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 130, 477-87  | 4.4  | 143  |
| 44 | Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1789-95 | 3.9  | 21   |
| 43 | Incorporating Agents that Target HER2 in the Neoadjuvant Setting. <i>Current Breast Cancer Reports</i> , <b>2011</b> , 3, 190-196   | 0.8  |      |

|    |  |      |      |
|----|--|------|------|
| 42 | Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. <i>BMC Cancer</i> , <b>2011</b> , 11, 131   | 4.8  | 76   |
| 41 | Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2150-7   | 2.2  | 67   |
| 40 | Can We Keep the 'PROMISE'? AGO Breast Commission: Commentary on Recent Evidence Regarding LHRH Analogues for the Preservation of Ovarian Function. <i>Breast Care</i> , <b>2011</b> , 6, 467-470   | 2.4  |      |
| 39 | Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2334-41   | 2.2  | 227  |
| 38 | Bevacizumab treatment for advanced breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1684-97  | 5.7  | 15   |
| 37 | The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 2141-9  | 4    | 6    |
| 36 | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3351-7 | 2.2  | 383  |
| 35 | Reply to L. Del Mastro and Z. Blumenfeld. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3341-3342  | 2.2  | 2    |
| 34 | Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. <i>Breast Care</i> , <b>2011</b> , 6, 457-461   | 2.4  | 2    |
| 33 | Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. <i>Cancer Research</i> , <b>2011</b> , 71, 3236-45  | 10.1 | 363  |
| 32 | Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2024-31  | 2.2  | 410  |
| 31 | Reply to F. Bellati et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e473-e473   | 2.2  | 1    |
| 30 | Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2634-45  | 12.9 | 401  |
| 29 | Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 83-91                                       | 2.2  | 52   |
| 28 | Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2015-23  | 2.2  | 173  |
| 27 | nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. <i>Expert Opinion on Drug Safety</i> , <b>2010</b> , 9, 515-23   | 4.1  | 13   |
| 26 | Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 105-13  | 2.2  | 1101 |
| 25 | Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 437-45   | 4.4  | 38   |

|    |  |      |     |
|----|--|------|-----|
| 24 | Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 124, 133-40              | 4.4  | 203 |
| 23 | Reply to A. Morabito et al and G. Valabrega et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e124-e125   | 2.2  | 2   |
| 22 | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1999-2006 | 2.2  | 596 |
| 21 | Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 953-8          | 3.5  | 4   |
| 20 | Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1452-9   | 12.9 | 494 |
| 19 | Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 616-24   | 2.4  | 34  |
| 18 | Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 542-51     | 9.7  | 235 |
| 17 | Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 552-62  | 9.7  | 199 |
| 16 | New Therapeutic Options for Breast Cancer during Pregnancy. <i>Breast Care</i> , <b>2008</b> , 3, 171-176  | 2.4  | 20  |
| 15 | Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design. <i>Breast Care</i> , <b>2008</b> , 3, 333-339   | 2.4  | 6   |
| 14 | NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. <i>Cancer Research</i> , <b>2008</b> , 68, 5159-66   | 10.1 | 62  |
| 13 | Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1115-22  | 12.9 | 59  |
| 12 | Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1940-9                                 | 2.2  | 488 |
| 11 | Darbepoetin alfa as primary prophylaxis of anemia in patients with breast cancer treated preoperatively with docetaxel/doxorubicin/cyclophosphamide. <i>Supportive Cancer Therapy</i> , <b>2006</b> , 3, 103-9                                 |      | 2   |
| 10 | Prevention Trials in Women at Moderate Risk of Breast Cancer. <i>Breast Care</i> , <b>2006</b> , 1, 298-303  | 2.4  | 1   |
| 9  | Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPAR DUO trial. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 1434-42   | 3.1  | 66  |
| 8  | Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 1702-10  | 3.1  | 298 |
| 7  | Use of goserelin in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 591-604  | 3.5  | 11  |

|   |  |     |     |
|---|--|-----|-----|
| 6 | Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. <i>Neoplasia</i> , <b>2004</b> , 6, 786-95  | 6.4 | 96  |
| 5 | Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. <i>Anti-Cancer Drugs</i> , <b>2003</b> , 14, 549-53  | 2.4 | 10  |
| 4 | EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2003</b> , 129, 250-1             | 4.9 | 4   |
| 3 | Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. <i>International Journal of Cancer</i> , <b>2002</b> , 101, 390-4   | 7.5 | 17  |
| 2 | Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. <i>Cancer</i> , <b>2002</b> , 95, 1191-8 | 6.4 | 59  |
| 1 | Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. <i>Oncogene</i> , <b>2002</b> , 21, 3162-71   | 9.2 | 142 |